Evidence map›Paper›PMID 34844180›Full record

GuidelineESMO open2021

Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck.

B Keam, J-P Machiels, H R Kim, L Licitra, W Golusinski, V Gregoire, Y G Lee, C Belka, Y Guo, S J Rajappa and 15 more

Registry-linked trialAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in ESMO open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06125223 (A Single-arm, Prospective, Phase II Study of PABLIXIMAB Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous-cell Carcinoma), which is not on this map. Cited by 43 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06125223 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

A Single-arm, Prospective, Phase II Study of PABLIXIMAB Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced Head and Neck Squamous-cell Carcinoma

TypeobservationalSponsorXijing HospitalRan2023 to 2026Enrolled45ConditionsSquamous Cell Carcinoma of Head and Neck, Neoadjuvant Therapy, Immunotherapy
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Development of depression in patients with oropharyngeal cancer: a systematic review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

B KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea. Electronic address: bhumsuk@snu.ac.kr.
J-P MachielsService d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
H R KimDivision of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
L LicitraHead and Neck Cancer Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy.
W GolusinskiDepartment of Head and Neck Surgery, Poznan University of Medical Sciences, The Greater Poland Cancer Centre, Poznan, Poland.
V GregoireDepartment of Radiation Oncology, Centre Léon Bérard, Lyon, France.
Y G LeeDivision of Hematology and Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
C BelkaDepartment of Radiation Oncology, LMU Hospital, Munich, Germany.
Y GuoDepartment of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
S J RajappaMedical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India.
M TaharaDepartment of Head and Neck Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
M AzrifClinical Oncology, Prince Court Medical Centre, Kuala Lumpur, Malaysia.
M K AngDepartment of Medical Oncology, National Cancer Centre, Singapore, Singapore.
M-H YangInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
C-H WangDivision of Hemato-oncology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
Q S NgDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
W I Wan ZamaniahClinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
N KiyotaOncology/Hematology, Cancer Center, Kobe University Hospital, Kobe, Japan.
S BabuDepartment of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, India.
K YangDepartment of Clinical Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
G CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Istituto Europeo di Oncologia, IRCCS, Milano, Italy.
S PetersDepartment of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
T W KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
T YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center East, Chiba, Japan.
G PentheroudakisESMO, Lugano, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of squamous cell carcinoma (SCC) of the oral cavity, larynx, oropharynx and hypopharynx was published in 2020. It was therefore decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special, virtual guidelines meeting in July 2021 to adapt the ESMO 2020 guidelines to consider the potential ethnic differences associated with the treatment of SCCs of the head and neck (SCCHN) in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with SCCHN (excluding nasopharyngeal carcinomas) representing the oncological societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence and was independent of the current treatment practices and drug access restrictions in the different Asian countries. The latter was discussed when appropriate. This manuscript provides a series of expert recommendations (Clinical Practice Guidelines) which can be used to provide guidance to health care providers and clinicians for the optimisation of the diagnosis, treatment and management of patients with SCC of the oral cavity, larynx, oropharynx and hypopharynx across Asia.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsFollow-Up StudiesHumansMedical OncologySquamous Cell Carcinoma of Head and NeckESMOguidelineshead and neckPan-Asiansquamous cell carcinomatreatment

Identifiers

PMID34844180
PMCPMC8710460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.